Merck and Co Inc/ US58933Y1055 /
2024-05-13 8:38:22 PM | Chg. -1.04 | Volume | Bid8:38:30 PM | Ask8:38:30 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
129.03USD | -0.80% | 3.58 mill. Turnover: 300.92 mill. |
129.01Bid Size: 100 | 129.02Ask Size: 300 | 326.72 bill.USD | 2.29% | 921.39 |
GlobeNewswire
05-08
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
04-24
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Onc...
GlobeNewswire
04-15
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
GlobeNewswire
04-09
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer...
GlobeNewswire
03-18
Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D...
GlobeNewswire
03-15
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire
03-06
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Can...
GlobeNewswire
02-07
Alleo Labs Announces Publication on the Use of Artificial Intelligence in Neuroscience Drug Discover...
GlobeNewswire
01-09
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted ...
GlobeNewswire
2023-12-21
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
GlobeNewswire
2023-12-04
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule